BioCryst Pharmaceuticals
BCRX
8.40
+0.45
+5.66%
BioCryst Pharmaceuticals
US · BCRX
#2766 by market cap
Listed 1970
8.40
+0.45
+5.66%
Live - 5344 symbols - heartbeat 461s ago
· 2026-10-08 07:05
Pre-market
8.32
-0.95%
After-hours
8.38
-0.24%
- Market cap
- 2.15B
- P/E (TTM)i
- -6.00
- P/Bi
- -4.72
- EPSi
- 1.21
- Div yieldi
- 0.00%
- 52W posi
- 46%
Reader sentiment
Are you bullish or bearish on BCRX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.31, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +94.10% YoY
Margins
- Gross margin
- 97.82%
- Operating margin
- 38.98%
- Net margin
- 30.16%
Key ratios & quality
- Enterprise valuei
- 2.30B
- Altman Z-Scorei
- 2.31
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 20.65M | 48.84M | 17.81M | 157.17M | 270.83M | 331.41M | 450.71M | 874.84M |
| Gross profit | 20.18M | 44.73M | 16.14M | 149.91M | 264.23M | 326.93M | 438.44M | 855.76M |
| Selling & admin expenses | 29.51M | 37.12M | 67.93M | 118.82M | 159.37M | 214.07M | 266.35M | 348.65M |
| Research & development | 84.89M | 107.07M | 122.96M | 208.81M | 253.30M | 216.57M | 174.64M | 166.13M |
| Operating profit | -94.22M | -99.46M | -174.76M | -177.72M | -148.44M | -103.71M | -2.54M | 340.99M |
| Pretax profit | -101.25M | -108.90M | -182.81M | -181.81M | -244.38M | -226.23M | -86.95M | 267.39M |
| Tax | -- | -- | 0 | 2.25M | 2.73M | 310.00K | 1.93M | 3.53M |
| Net profit | -101.25M | -108.90M | -182.81M | -184.06M | -247.12M | -226.54M | -88.88M | 263.86M |
| Basic EPS | -1 | -1 | -1 | -1 | -1 | -1 | 0 | 1 |
| Diluted EPS | -0.98 | -0.94 | -1.09 | -1.03 | -1.33 | -1.18 | -0.43 | 1.21 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 145.53M | 163.35M | 159.40M | 406.56M | 156.41M | 218.25M |
| Gross profit | 140.97M | 160.56M | 157.21M | 397.03M | 151.04M | 214.41M |
| Selling & admin expenses | 82.47M | 87.38M | 83.01M | 95.78M | 94.55M | 63.98M |
| Research & development | 37.27M | 43.39M | 44.60M | 40.87M | 758.08M | 51.97M |
| Operating profit | 21.23M | 29.79M | 29.59M | 260.39M | -701.60M | 98.47M |
| Pretax profit | 758.00K | 6.49M | 12.13M | 248.02M | -720.81M | 79.47M |
| Tax | 726.00K | 1.40M | -769.00K | 2.17M | 1.00M | 1.08M |
| Net profit | 32.00K | 5.09M | 12.90M | 245.85M | -721.81M | 78.40M |
| Basic EPS | 0 | 0 | 0 | 1 | -3 | 0 |
| Diluted EPS | 0.00 | 0.02 | 0.06 | 1.12 | -2.98 | 0.30 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 114.35M | 164.35M | 323.80M | 566.14M | 516.50M | 495.97M | 421.97M | 404.35M |
| Cash & ST investments | 104.47M | 136.23M | 300.37M | 507.60M | 424.31M | 388.99M | 320.85M | 274.75M |
| Inventory | 1.65M | 0 | 7.04M | 15.79M | 27.53M | 28.68M | 8.09M | 5.40M |
| Total assets | 146.84M | 175.28M | 334.72M | 588.15M | 550.00M | 516.96M | 490.42M | 514.16M |
| Total current liabilities | 69.48M | 92.34M | 105.65M | 103.72M | 105.51M | 149.99M | 160.38M | 196.07M |
| Short-term debt | 33.75M | 39.96M | 31.18M | 1.82M | 2.37M | 2.65M | 2.77M | 1.63M |
| Long-term debt | 25.37M | 41.29M | 244.45M | 585.46M | 733.28M | 811.27M | 795.92M | 427.23M |
| Total liabilities | 97,606,000.00 | 137,030,000.00 | 353,977,000.00 | 695,137,000.00 | 844,597,000.00 | 972,488,000.00 | 966,354,000.00 | 633,311,000.00 |
| Total equity | 49.24M | 38.25M | -19.26M | -106.99M | -294.60M | -455.53M | -475.93M | -119.15M |
| Retained earnings | -731.97M | -840.63M | -1.02B | -1.21B | -1.45B | -1.68B | -1.77B | -1.51B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 409.98M | 398.46M | 355.68M | 404.35M | 373.63M | 484.68M |
| Cash & ST investments | 295.09M | 260.04M | 212.87M | 274.75M | 238.40M | 352.57M |
| Inventory | 6.87M | 5.04M | 5.23M | 5.40M | 5.99M | 6.06M |
| Total assets | 480.05M | 457.19M | 446.42M | 514.16M | 465.05M | 557.85M |
| Total current liabilities | 139.86M | 177.16M | 190.24M | 196.07M | 195.39M | 208.85M |
| Short-term debt | 2.87M | 2.01M | 1.78M | 1.63M | 3.09M | 3.00M |
| Long-term debt | 782.03M | 690.64M | 633.47M | 427.23M | 802.38M | 778.38M |
| Total liabilities | 931,974,000.00 | 878,782,000.00 | 834,313,000.00 | 633,311,000.00 | 1,018,895,000.00 | 1,012,140,000.00 |
| Total equity | -451.93M | -421.59M | -387.89M | -119.15M | -553.84M | -454.29M |
| Retained earnings | -1.77B | -1.76B | -1.75B | -1.51B | -2.23B | -2.15B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -92.57M | -89.58M | -135.11M | -142.16M | -161.85M | -95.14M | -52.02M | 347.37M |
| Depreciation & amortization | 770.00K | 724.00K | 748.00K | 777.00K | 1.44M | 1.66M | 1.25M | 1.39M |
| Free cash flow | -92.93M | -89.93M | -135.62M | -144.54M | -163.20M | -97.31M | -53.14M | 344.90M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 53.40M | 58.50M | 93.28M | 50.06M | 190.00K | 342.00K | 34.00K | 59.00K |
| Ending cash balance | 28.28M | 115.72M | 274.35M | 507.73M | 306.24M | 112.45M | 106.32M | 91.34M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -27.52M | 41.30M | 41.62M | 291.96M | -61.79M | 104.34M |
| Depreciation & amortization | 331.00K | 329.00K | 335.00K | 394.00K | 461.00K | 513.00K |
| Free cash flow | -27.66M | 41.12M | 40.28M | 291.16M | -62.19M | 104.13M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 6.00K | 9.00K | 21.00K | 23.00K | 33.00K | 44.00K |
| Ending cash balance | 106.88M | 89.93M | 86.06M | 91.34M | 173.38M | 156.38M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -152.26 | -248.94 | -1,925.37 | -- | -- | -- | -- | -- |
| ROA %i | -62.29 | -67.61 | -71.69 | -39.89 | -43.42 | -42.46 | -17.65 | 52.53 |
| ROIC %i | -75.60 | -84.58 | -92.78 | -- | -- | -- | -- | -- |
| 5-year avg ROE %i | -144.23 | -169.76 | -540.89 | -- | -- | -- | -- | -- |
| EBIT margin %i | -445.82 | -198.64 | -944.94 | -77.95 | -53.65 | -35.60 | 2.57 | 39.58 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | 39.42 |
| Current ratioi | 1.65 | 1.78 | 3.06 | 5.46 | 4.90 | 3.31 | 2.63 | 2.06 |
| Quick ratioi | 1.57 | 1.72 | 2.92 | 5.18 | 4.50 | 2.97 | 2.49 | 1.95 |
| Debt / assetsi | 42.10 | 48.30 | 83.50 | 100.86 | 134.81 | 159.62 | 164.91 | 85.36 |
| LT debt / equityi | 57.02 | 116.84 | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -10.03 | -8.16 | -11.61 | -2.07 | -1.47 | -1.09 | 0.12 | 4.39 |
| Revenue CAGR (3Y) %i | -24.64 | 22.83 | -10.91 | 96.70 | 77.01 | 164.98 | 42.07 | 47.82 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -- | -- |
| ROA %i | -11.28 | -7.68 | -1.87 | 52.53 | -96.92 | -75.79 |
| ROIC %i | -- | -- | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 9.20 | 11.15 | 13.77 | 39.58 | -42.79 | -32.52 |
| FCF / sales %i | -- | 2.83 | 7.98 | 39.42 | 35.04 | 39.70 |
| Current ratioi | 2.93 | 2.25 | 1.87 | 2.06 | 1.91 | 2.32 |
| Quick ratioi | 2.78 | 1.98 | 1.60 | 1.95 | 1.78 | 2.22 |
| Debt / assetsi | 165.61 | 153.80 | 144.58 | 85.36 | 175.84 | 142.12 |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | 0.48 | 0.66 | 0.93 | 4.39 | -5.04 | -4.06 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Single segment100.00%
Quote time 2026-10-08 07:05:56 · For reference only, not investment advice and not tailored to your situation.